Hereditary cerebral hemorrhage with amyloidosis (HCHWA) describes a group of rare familial central nervous system disorders characterized by amyloid deposition in the cerebral blood vessels leading to...
Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
The documentation on cerebral amyloid angiopathy is limited primarily due to its extreme rarity, affecting fewer than 1 in 1,000,000 individuals worldwide. This rarity results in a lack of systematic clinical studies and comprehensive phenotype documentation. Additionally, the genetic basis of the condition is still being characterized, which contributes to the challenges in understanding its clinical features fully.
To navigate cerebral amyloid angiopathy, consider consulting a neurologist with expertise in hereditary cerebral vascular disorders. Genetic counseling may also be beneficial, especially given the involvement of known genes such as ITM2B, CST3, and APP. While there are currently no patient organizations specifically identified for CAA, resources like the Genetic and Rare Diseases Information Center (GARD) can provide valuable information and support. You can access GARD at rarediseases.info.nih.gov for additional guidance and resources.
Currently, there are 14 active clinical trials investigating various aspects of cerebral amyloid angiopathy. These trials explore potential treatments and interventions aimed at managing the condition. You can find more information and search for specific trials at ClinicalTrials.gov using this link: https://clinicaltrials.gov/search?cond=cerebral%20amyloid%20angiopathy.
Actionable guidance for navigating care for cerebral amyloid angiopathy
To navigate cerebral amyloid angiopathy, consider consulting a neurologist with expertise in hereditary cerebral vascular disorders. Genetic counseling may also be beneficial, especially given the involvement of known genes such as ITM2B, CST3, and APP. While there are currently no patient organizations specifically identified for CAA, resources like the Genetic and Rare Diseases Information Center (GARD) can provide valuable information and support. You can access GARD at rarediseases.info.nih.gov for additional guidance and resources.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 2 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.